NVCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Nuvectis Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Nuvectis Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Nuvectis Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $12.20 Mil. Nuvectis Pharma's debt to equity for the quarter that ended in Dec. 2023 was 0.00.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nuvectis Pharma's Debt-to-Equity or its related term are showing as below:
The historical data trend for Nuvectis Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvectis Pharma Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Debt-to-Equity | - | - | - | - |
Nuvectis Pharma Quarterly Data | ||||||||||||
Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-Equity | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Nuvectis Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nuvectis Pharma's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Nuvectis Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0 | + | 0) | / | 12.201 | |
= | 0.00 |
Nuvectis Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0 | + | 0) | / | 12.201 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvectis Pharma (NAS:NVCT) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Nuvectis Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Ron Bentsur | director, officer: Chairman & CEO | 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022 |
Marlio Charles Mosseri | 10 percent owner | 27 RIPPLEVALE GROVE, LONDON X0 N1 1HS |
Enrique Poradosu | officer: Chief Science and Business Off | C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024 |
Shay Shemesh | officer: Chief Development Officer | C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024 |
Michael J. Carson | officer: Vice President, Finance | C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024 |
Kenneth Hoberman | director | 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024 |
Oliviero James F Iii | director | C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Uri Ben-or | officer: Int. Principal Financial Off. | C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Matthew L. Kaplan | director | C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024 |
From GuruFocus
By Marketwired • 09-01-2023
By sperokesalga sperokesalga • 06-20-2023
By GuruFocus Research GuruFocus Editor • 05-18-2023
By sperokesalga sperokesalga • 04-18-2023
By PurpleRose PurpleRose • 08-05-2022
By Stock market mentor Stock market mentor • 01-04-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
By sperokesalga sperokesalga • 02-09-2023
By Marketwired • 08-17-2023
By sperokesalga sperokesalga • 02-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.